For patients with chronic obstructive pulmonary disease (COPD) with a history of ... Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab (419 ...

Former smokers with COPD reporting higher perceived stress had poorer scores on respiratory health assessments, according to ...

As chronic obstructive pulmonary disease (COPD) gets worse ... Like the disease itself, flare-ups may range from mild to severe. Your doctor will help you come up with a plan for how to handle ...

Among patients with prior severe exacerbations, Nucala reduced the annualised rate of moderate ... exacerbation risk profiles and reinforce the therapeutic relevance of IL-5 inhibition in COPD ...

Doctors use stages or grades to describe how severe ... and exacerbation risk – your doctor will put your COPD into one of these groups: Group A (GOLD 1 or 2): Your symptoms are very mild.

Mepolizumab significantly reduced the annualized rate of moderate or severe ... among patients with COPD who had been admitted to the hospital with a severe exacerbation and a blood eosinophil ...

Whereas the GOLD 2022 report noted the efficacy of LABA+ICS in patients with moderate ... mild disease and GOLD 4 signifying very severe disease. 27 The mean (SD) annual COPD-related medical ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a ...